Salmon “sperm DNA” skincare: does PDRN actually work, or is it just hype?

What PDRN actually is — and the “sperm” in salmon sperm DNA

PDRN stands for polydeoxyribonucleotide: a mixture of DNA fragments, typically purified from the gonadal tissue of salmon or trout. That sourcing is exactly where the viral “salmon sperm DNA” nickname comes from — salmon milt is a cheap, abundant, highly standardizable source of long DNA strands, and those strands are then broken down into shorter chains, deproteinized and sterilized into a medical-grade material. The fish origin matters less than people assume: DNA is DNA, and the salmon DNA is chosen because it is chemically reliable and low-immunogenicity, not because anything “fishy” survives the purification. A closely related cousin, polynucleotide (PN), is essentially a longer, more highly purified version of the same idea; in the aesthetics world the terms PDRN and PN are often used loosely, and brands like Rejuran sit in the polynucleotide camp.¹

None of that backstory tells you whether it works. What makes PDRN more than “fish DNA in a vial” is that those DNA fragments are biologically active — they engage a specific receptor and feed a specific metabolic pathway. The catch, which the trend almost never mentions, is that this activity only counts if the molecule gets to the cells that have those receptors. And that is where the single most important fact about PDRN lives.

The whole story: two products wearing one name

Almost every argument about PDRN evaporates the moment you separate the two formats, because they are not the same product with two delivery methods — they are two different propositions.

Injectable PDRN is a medical procedure. A trained provider injects the material into the dermis — via microinjection, mesotherapy-style technique, or a filler-like placement — depositing it directly among the fibroblasts it is meant to act on. This is the form with names attached: Placentex in the wound-healing literature, Rejuran and similar in the skin-rejuvenation market. The molecule bypasses the skin barrier entirely because the needle does the delivery. Every piece of strong clinical PDRN evidence — the randomized wound trials, the rejuvenation studies — comes from this format.³⁴

Topical PDRN is a cosmetic. It is the same nominal ingredient dropped into a serum, ampoule, cream or sheet mask, sold over the counter, and applied to intact skin. This is the form fuelling the TikTok wave. And it inherits a fundamental physics problem: the molecule it is built around is large, and the outer skin layer — the stratum corneum — evolved precisely to keep large, water-loving molecules out. The two formats share a name and a marketing story; they do not share an evidence base.⁶

PDRN by needle and PDRN in a jar are not the same thing with two delivery routes. They are two different products that happen to share a viral name — and only one of them has the trial data the other borrows.

The mechanism: A2A receptor and the salvage pathway

This is the one section where the receptor-and-pathway vocabulary earns its place, because the mechanism is genuinely the strongest part of the PDRN story. PDRN works through two complementary routes. First, its fragments act as an adenosine A2A receptor agonist: by engaging the A2A receptor on fibroblasts and other cells, PDRN turns up the signal for collagen production, fibroblast proliferation and angiogenesis — the growth of new blood vessels — while damping pro-inflammatory mediators.¹ Early pharmacology pinned this down directly: PDRN enhanced the proliferation of human skin fibroblasts in culture, and that effect ran through A2 purinergic receptor subtypes, because blocking the receptor blocked the growth signal.²

Second, the DNA fragments themselves serve as raw material through the salvage pathway — the cell’s recycling route for nucleotides. Cells building and repairing tissue need a supply of nucleotides, and the salvage pathway lets them reuse pre-formed purine and pyrimidine bases rather than synthesizing every one from scratch. PDRN’s breakdown products feed straight into that pathway, supplying the building blocks for DNA synthesis in cells that are dividing and repairing.¹ Together, the A2A signal and the salvage substrate make a coherent “repair” rationale.

Here is the load-bearing caveat. A receptor on a fibroblast in the dermis is no use to a molecule that never reaches the dermis. The mechanism is real, well-described and consistent across tissue models — but it is a mechanism that fires at the cellular level, which means delivery is not a footnote, it is the entire question. Injected into the dermis, the mechanism has a plausible path to act. Smeared on top of an intact barrier, it has to cross that barrier first, and that is exactly the step topical PDRN has not shown.

The injectable evidence: wounds, then faces

The deepest PDRN data does not come from beauty at all — it comes from wound healing, where the bar for evidence is higher. The standout is a randomized, double-blind, placebo-controlled trial in patients with chronic, hard-to-heal diabetic foot ulcers, run across Italian centers. PDRN-treated patients reached complete healing at roughly twice the rate of placebo (about 37% versus 19%), with faster time to closure and greater epithelialized area, alongside improved tissue oxygenation and angiogenesis.⁴ That is the kind of controlled, hard-endpoint result the cosmetic literature rarely produces, and it anchors the “PDRN genuinely supports repair” claim.

The skin-rejuvenation case is real but softer. A 2025 systematic review of polynucleotides in esthetic medicine pooled the clinical studies of injected PN/PDRN for skin rejuvenation and found statistically significant improvements in wrinkle appearance, skin texture and elasticity within about three months, with adverse events limited to mild, transient injection-site swelling, redness and bruising.³ Encouraging — but the same reviewers are blunt about the quality: most of the underlying trials are small, short, single-center, and frequently lack proper blinding or a placebo arm, so the body of evidence is graded low-to-moderate.³ A separate review of aesthetic practice echoes the pattern: real clinician-reported and patient-reported benefit, thin high-quality trial backing.⁵

So the injectable verdict is a careful yes: strong, controlled evidence in wound healing, and a consistent-but-modest, lower-quality body of evidence for facial rejuvenation. It is “real signal, not yet rigorous proof” for the cosmetic use, and genuinely solid for repair.

The topical gap: where the trend overshoots

Now the part the 1.9-million-posts-a-week trend skips. The viral “salmon DNA serum” is topical, and topical PDRN faces a wall the injectable simply walks through with a needle. The active is a large molecule; the stratum corneum is built to exclude large, hydrophilic molecules; and the strong clinical PDRN evidence was, almost without exception, generated by injection into the dermis — not by application to intact skin.⁶ The crucial number — how much intact active actually reaches living dermis from a leave-on product — is largely undocumented in independent, peer-reviewed work.

That does not mean topical PDRN products do nothing. A serum is more than its headline ingredient, and the supporting formula — humectants, occlusives, sometimes added niacinamide or vitamin C — can genuinely hydrate, smooth and improve the look of skin. A 2022 study of a topical PDRN-containing mixture (combined with vitamin C and niacinamide) reported improved elasticity and reduced pigmentation; but it tested a multi-ingredient formula, so it cannot isolate the PDRN, and two of its three ingredients are independently active skin agents.⁶ The honest read: a topical “salmon DNA” serum behaves about like a good moisturizer with some pleasant secondary actives — useful, but not the regenerative injectable in a bottle. The marketing that implies otherwise is borrowing the needle’s evidence to sell a cream.

Where it fits: a tiered view

These tiers describe what clinics and trials have actually used, not a prescription for what you should do.

Foundational — the non-negotiables first. Nothing in this article competes with daily broad-spectrum sunscreen, which has the strongest evidence of anything in photoaging prevention, plus not smoking and adequate sleep. PDRN in any form is something you add on top of prevention, never a substitute for it. If sunscreen isn’t daily, that is the higher-yield move, every time.

Research-curious — the in-clinic injectable, eyes open. The format with actual data is the clinic-administered injectable, performed by a licensed provider. The trials that exist used this route, for skin texture, elasticity and — most robustly — wound repair.³⁴ If someone is considering it, the realistic expectation is a modest, gradual improvement on lower-to-moderate-quality cosmetic evidence, not a transformation. It is a procedure with real (if mild) risks and real cost.

Experimental — expecting the serum to do the injectable’s job. Treating a topical PDRN serum as equivalent to the injectable runs well ahead of the evidence. The penetration step that the whole rejuvenation claim depends on is exactly the step topical products have not demonstrated.⁶ As a hydrating step it is fine; as a stand-in for the clinical procedure, it is the weakest-supported use of all.

Grey areas: cost, sourcing, regulation, marketing

It is in-clinic and not cheap. The evidence-backed version is a course of injections delivered by a trained provider, usually several sessions, at a cost that compounds. That is a different commitment from a $30 serum, and it is the version the data actually supports — a point the social-media framing tends to blur by showing serums while citing injectable results.

Sourcing and standardization vary. “PDRN” or “polynucleotide” on a label tells you a class of molecule is present, not its molecular weight, purity, concentration, or how it was processed — all of which plausibly affect activity. Medical-grade injectables used in trials are tightly specified products; an over-the-counter serum is not the same material at the same dose, and should not be expected to behave like one.¹

Regulation is uneven. Injectable polynucleotides occupy different regulatory categories in different countries — medical device in some, drug-adjacent in others — and approval status for cosmetic skin rejuvenation is not uniform. Topical cosmetics face a far lower evidentiary bar than injectables, which is part of why marketing claims for the serums can be so confident while the supporting data stays so thin.

The marketing borrows the needle’s evidence. The recurring sleight of hand in this trend is citing injectable, clinic-grade results to sell topical, over-the-counter products. The measurements in the injectable studies are real. They were just not made on the product most people are buying.

What we don’t know yet

Topical penetration is the central unanswered question. There is no robust, independent body of work showing that intact PDRN crosses the human stratum corneum in meaningful amounts from a leave-on product, or that any topical PDRN serum reproduces the injectable’s rejuvenation outcomes in a controlled trial.⁶ Until that exists, the topical claims rest on extrapolation from the needle.

The cosmetic injectable evidence needs upgrading. The rejuvenation case is built on small, short, frequently unblinded studies graded low-to-moderate quality by its own reviewers.³ Large, well-blinded, placebo-controlled trials with durable follow-up — the standard the diabetic-foot-ulcer work met — have not yet been run for facial rejuvenation at scale.

Durability, head-to-head and population gaps. We have thin data on how long injectable benefits last after a course ends, on direct comparisons against established options like a retinoid or hyaluronic-acid skin booster, and across the full range of skin tones and ages. Those are the comparisons that would tell us where injectable PDRN truly ranks rather than simply that it does something.

What this article is not saying

This is not “PDRN is a scam.” The mechanism is sound, the wound-healing data is genuinely strong, and the injectable rejuvenation signal is real if modest. Dismissing all of it is as wrong as the hype.

This is not “your salmon DNA serum is doing what the clinic injection does.” The injectable bypasses the barrier the topical has to cross, and the topical has not shown it crosses it. Your serum is most honestly described as a good moisturizer with some pleasant extras — not a needle in a bottle. For context on actives that do have deep topical data, our reads on tretinoin⁷, niacinamide and the gentler bakuchiol set the benchmark.

And this is not a recommendation to book injections or buy a serum. It is a map of where the evidence is solid (injectable repair), where it is promising-but-thin (injectable rejuvenation), and where it largely runs out (topical). If you are weighing an in-clinic procedure, that is a conversation with a licensed provider — informed by the rest of the skin and aging toolkit, not by a trending hashtag.